Jerry Nedelman1,2, Roland Fisch3,4, Ke Hu1,5, Ines Paule3, Jocelyn Zhou6,7. 1. Oncology Clinical Pharmacology, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA. 2. TB Alliance, 40 Wall St # 24, New York, NY, 10005, USA. 3. Modeling and Simulation, Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland. 4. Im Rotländ 21, CH-4112, Flüh, Switzerland. 5. Rafael Pharmaceuticals, 520 Broad St, Newark, NJ, 07102, USA. 6. Oncology Clinical Pharmacology, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA. jocelyn.zhou@novartis.com. 7. Novartis Sandoz Division, 100 College Road West, Princeton, NJ, USA. jocelyn.zhou@novartis.com.
Abstract
BACKGROUND AND OBJECTIVE: Pasireotide (SOM230, Signifor®) is a somatostatin analog approved in a subcutaneous formulation for the treatment of Cushing's disease. This analysis characterizes the population pharmacokinetics (PopPK) of subcutaneous pasireotide jointly in healthy volunteers (HVs) and Cushing's disease patients (CDPs), evaluating the effects of age, body size, and population on pasireotide pharmacokinetics. METHODS: The analysis dataset included five phase I studies and one each from phase II and phase III. A three-compartment, linear structural pharmacokinetic model was used. Models were specified a priori that varied in the relationship between HVs and CDPs, and the model with the lowest value of the Bayes Information Criterion (BIC) was selected. It was then used to illustrate various features of pasireotide pharmacokinetics. RESULTS AND CONCLUSIONS: In the final model, the estimated values of apparent clearance (CL/F), central volume of distribution, and deep peripheral volume of distribution of pasireotide in CDP were 59, 43, and 225% those of HVs at the same age and body size. Clearance increased with body size and decreased with age similarly for CDPs and HVs. The estimated CL/F for a typical CDP (40 years old, lean body weight [LBW] 49 kg) was 3.72 L/h, and for a typical HV (29 years old, LBW 61 kg) was 7.96 L/h. The model was judged adequate by visual predictive checks and diagnostic plots separately for HVs and CDPs and can be used for simulations for deriving exposure-response metrics for pharmacokinetic/pharmacodynamic analyses.
BACKGROUND AND OBJECTIVE: Pasireotide (SOM230, Signifor®) is a somatostatin analog approved in a subcutaneous formulation for the treatment of Cushing's disease. This analysis characterizes the population pharmacokinetics (PopPK) of subcutaneous pasireotide jointly in healthy volunteers (HVs) and Cushing's diseasepatients (CDPs), evaluating the effects of age, body size, and population on pasireotide pharmacokinetics. METHODS: The analysis dataset included five phase I studies and one each from phase II and phase III. A three-compartment, linear structural pharmacokinetic model was used. Models were specified a priori that varied in the relationship between HVs and CDPs, and the model with the lowest value of the Bayes Information Criterion (BIC) was selected. It was then used to illustrate various features of pasireotide pharmacokinetics. RESULTS AND CONCLUSIONS: In the final model, the estimated values of apparent clearance (CL/F), central volume of distribution, and deep peripheral volume of distribution of pasireotide in CDP were 59, 43, and 225% those of HVs at the same age and body size. Clearance increased with body size and decreased with age similarly for CDPs and HVs. The estimated CL/F for a typical CDP (40 years old, lean body weight [LBW] 49 kg) was 3.72 L/h, and for a typical HV (29 years old, LBW 61 kg) was 7.96 L/h. The model was judged adequate by visual predictive checks and diagnostic plots separately for HVs and CDPs and can be used for simulations for deriving exposure-response metrics for pharmacokinetic/pharmacodynamic analyses.
Authors: Annamaria Colao; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Ulrike Schoenherr; David Mills; Luiz Roberto Salgado; Beverly M K Biller Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Rosario Pivonello; Andrea M Isidori; Maria Cristina De Martino; John Newell-Price; Beverly M K Biller; Annamaria Colao Journal: Lancet Diabetes Endocrinol Date: 2016-05-10 Impact factor: 32.069
Authors: M Boscaro; W H Ludlam; B Atkinson; J E Glusman; S Petersenn; M Reincke; P Snyder; A Tabarin; B M K Biller; J Findling; S Melmed; C H Darby; K Hu; Y Wang; P U Freda; A B Grossman; L A Frohman; J Bertherat Journal: J Clin Endocrinol Metab Date: 2008-10-28 Impact factor: 5.958
Authors: Georg Golor; Ke Hu; Matthieu Ruffin; Alexandra Buchelt; Emmanuel Bouillaud; Yanfeng Wang; Mario Maldonado Journal: Drug Des Devel Ther Date: 2012-04-19 Impact factor: 4.162